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tion of the septum around the pedicle. An atrial septal defect,
caused by the tumor excision maneuver, was closed with
Dacron fabric. Histologic features of the tumor were typical
of a cardiac myxoma. The patient’s postoperative recovery
was uneventful. The IL-6 serum level decreased rapidly after
the operation and remained in the normal range (<5 pg/mL)
until the last measurement done in February 1997. The con-
stitutional symptoms permanently disappeared.
In October 1997 she was readmitted because of a 1-week
history of general malaise, arthralgias, night sweats, and
anorexia. She denied cough, cardiovascular, respiratory, or
abdominal symptoms. Her temperature was 38.5°C; the
remainder of the physical examination was normal.
Hemoglobin level was 10.8 g/dL, white blood cell count
7500/mm3, platelet count 576,000/mm3, and erythrocyte sed-
imentation rate 90 mm/h. The gamma globulin level was
25.2%, immunoglobulin G 1970 mg/dL, C-reactive protein
12.7 mg/dL, and the IL-6 serum level 77 pg/mL.
Two-dimensional echocardiography revealed a left atrial
mass attached to the posterior wall. The lesion was mobile and
did not interfere with the mitral valve. Subsequently, a second
operation was performed. The recurrent pedunculated mass
(dimensions, 36 × 31 × 28 mm) was excised together with an
additional cuff of atrial tissue, and the defect was repaired.
Histologically, the tumor was a typical benign myxoma and
indistinguishable from the previous lesion.
Comment. The malignant potential of cardiac myxomas is
controversial. Cardiac myxomas are usually considered benign,
but recurrences, multicentricity, and distant metastases have
been documented,3 suggesting that cardiac myxomas may have
an intrinsic malignant potential. Since IL-6 is known to be con-
stitutively produced and secreted by cardiac myxoma cells, it
has been hypothesized that IL-6 might be used as a marker of
myxoma.4 One study5 showed that the amount of circulating IL-
6 directly depends on the tumor size, that is, on the number of
IL-6–producing myxoma cells. In the present case, the observed
correlation between tumor size and IL-6 is lost with tumor recur-
rence, as evidenced by the presence of high IL-6 serum levels
associated with a smaller recurrent tumor. These higher levels of
IL-6 at the time of recurrence correlated well with the develop-
ment of more intense constitutional abnormalities. Whether the
IL-6 serum levels indicate the presence of an underlying more
aggressive disorder or a direct responsibility for future recur-
rences (or both) is unknown.
Cardiac myxomas produce and secrete interleukin 6 (IL-6),
which may be a possible explanation for the inflammatory and
immune features observed in most patients affected by these
tumors.1 In addition to explaining the presence of constitu-
tional symptoms, IL-6 could have a potential role in tumor
recurrence. Since IL-6 induces cell proliferation,2 the question
is whether a cardiac myxoma that produces high levels of this
cytokine may have a higher rate of recurrence. This could be
of special interest because the histologic appearance of the
tumor cannot predict local or remote recurrence. The answer
to this question will be obtained only by studying the evolu-
tion of patients with cardiac myxomas that produce high lev-
els of IL-6. Herein, we present a case of tumor recurrence that
was monitored along with regular measurements of IL-6
serum levels.
Clinical summary. A 15-year-old girl was admitted to the
Guillermo Almenara Hospital in September 1994 with a 2-
week history of fever, general malaise, fatigue, and peripher-
al edema. Her temperature was 38.2°C, erythrocyte sedimen-
tation rate 67 mm/h, white blood cell count 6200/mm3,
hemoglobin level 12.1 g/dL, and platelet count 483,000/mm3.
The gamma globulin level was 22.6%, immunoglobulin G
level 1825 mg/dL, C-reactive protein level 7.5 mg/dL, and IL-
6 serum level 39 pg/mL. No family history of myxoma was
noted. A giant right atrial tumor was revealed by 2-dimen-
sional echocardiography.
The patient underwent a cardiac operation in which a 63 ×
62 × 60 mm tumor was removed in addition to the underlying
atrial septal endocardium. The tumor was excised with a por-
INTERLEUKIN-6 PRODUCTION AND RECURRENT CARDIAC MYXOMA
Cesar Emilio Mendoza, MD,a Manuel Francisco Rosado, MD,a and Primo Pacheco, MD,b Miami, Fla, and Lima, Peru
From the Department of Internal Medicine Division, Jackson
Memorial Hospital, University of Miami School of Medicine,
Miami, Fla, and Cardiothoracic Surgery Division, Guillermo
Almenara Hospital, Lima, Peru. 
Received for publication March 13, 2000; accepted for publication
March 23, 2000.
Address for reprints: Cesar Emilio Mendoza, MD, Internal Medicine
Residency Program, Jackson Memorial Hospital, 1611 NW 12th
Ave, Miami, FL 33136-1094 (E-mail: pathoyosg@mixmail.com).
J Thorac Cardiovasc Surg 2001;121:395-6
Copyright © 2001 by The American Association for Thoracic
Surgery
0022-5223/2001 $35.00 + 0 12/54/109704
doi:10.1067/mtc.2001.109704
396 Brief communications The Journal of Thoracic and
Cardiovascular Surgery
February 2001
In summary, this case demonstrates that IL-6 may play an
important role in cardiac myxoma recurrence and suggests
that recurrent tumors could represent a subgroup of myxomas
that are intrinsically more aggressive. Future studies are war-
ranted to investigate the biologic behavior of these interesting
tumors.
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